Theodora Bejan-Angoulvant

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. doi Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
    Theodora Bejan-Angoulvant
    Hospices Civils de Lyon, Service de Biostatistiques, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Eur J Epidemiol 23:251-9. 2008
  2. doi Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials
    Theodora Bejan-Angoulvant
    Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France
    J Hypertens 28:1366-72. 2010
  3. pmc Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    PLoS Med 9:e1001204. 2012
  4. doi Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial
    Caroline Scholtes
    Hospices Civils de Lyon, Hopital de la Croix Rousse, Laboratory of Virology, Lyon, France
    Therapie 67:423-7. 2012
  5. ncbi The IDEAL study : towards personalized drug treatment of hypertension
    Theodora Bejan-Angoulvant
    Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France UMR 5558, CNRS, Villeurbanne, France Claude Bernard Lyon 1 University, Lyon, France
    Therapie 67:195-204. 2012
  6. pmc Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    BMJ 343:d4169. 2011
  7. doi Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study
    Theodora Bejan-Angoulvant
    Pharmacologie Clinique, Hospices Civils de Lyon, Lyon, France
    Nephrol Dial Transplant 27:2886-91. 2012

Collaborators

Detail Information

Publications7

  1. doi Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
    Theodora Bejan-Angoulvant
    Hospices Civils de Lyon, Service de Biostatistiques, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Eur J Epidemiol 23:251-9. 2008
    ..They provided two different points of view of the same phenomenon: recent years of diagnosis had a favourable effect on survival, but not on cure...
  2. doi Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials
    Theodora Bejan-Angoulvant
    Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France
    J Hypertens 28:1366-72. 2010
    ..However, inconsistencies exist with regard to the effect of these drugs on total mortality...
  3. pmc Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    PLoS Med 9:e1001204. 2012
    ..Since then, it has been the first-line treatment in overweight patients with type 2 diabetes. However, metformin-sulphonylurea bitherapy may increase mortality...
  4. doi Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial
    Caroline Scholtes
    Hospices Civils de Lyon, Hopital de la Croix Rousse, Laboratory of Virology, Lyon, France
    Therapie 67:423-7. 2012
    ..To test the modulation of farnesoid X receptor activity on the replication of hepatitis C virus in chronically infected patients...
  5. ncbi The IDEAL study : towards personalized drug treatment of hypertension
    Theodora Bejan-Angoulvant
    Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France UMR 5558, CNRS, Villeurbanne, France Claude Bernard Lyon 1 University, Lyon, France
    Therapie 67:195-204. 2012
    ..To identify markers (phenotypic, genetic, or environmental) of blood pressure (BP) response profiles to angiotensin converting enzyme inhibitors (ACEIs) and diuretics...
  6. pmc Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    BMJ 343:d4169. 2011
    ..To determine all cause mortality and deaths from cardiovascular events related to intensive glucose lowering treatment in people with type 2 diabetes...
  7. doi Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study
    Theodora Bejan-Angoulvant
    Pharmacologie Clinique, Hospices Civils de Lyon, Lyon, France
    Nephrol Dial Transplant 27:2886-91. 2012
    ..No study has investigated the presence of MMD and its clinical impact in ESRD patients...